AU2021401231A1 - Compositions and methods for modulating myc expression - Google Patents

Compositions and methods for modulating myc expression Download PDF

Info

Publication number
AU2021401231A1
AU2021401231A1 AU2021401231A AU2021401231A AU2021401231A1 AU 2021401231 A1 AU2021401231 A1 AU 2021401231A1 AU 2021401231 A AU2021401231 A AU 2021401231A AU 2021401231 A AU2021401231 A AU 2021401231A AU 2021401231 A1 AU2021401231 A1 AU 2021401231A1
Authority
AU
Australia
Prior art keywords
expression
sequence
repressor
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021401231A
Other languages
English (en)
Inventor
Houda BELAGHZAL
Jeremiah Dale FARELLI
Jodi Michelle KENNEDY
Eugine Lee
Adam Walter SCHEIDEGGER
Jr. William Thomas SENAPEDIS
Abigail Elizabeth WITT
Defne YARAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flagship Pioneering Innovations V Inc
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of AU2021401231A1 publication Critical patent/AU2021401231A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
AU2021401231A 2020-12-15 2021-12-15 Compositions and methods for modulating myc expression Pending AU2021401231A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063125833P 2020-12-15 2020-12-15
US63/125,833 2020-12-15
US202163137097P 2021-01-13 2021-01-13
US63/137,097 2021-01-13
US202163212991P 2021-06-21 2021-06-21
US63/212,991 2021-06-21
US202163281022P 2021-11-18 2021-11-18
US63/281,022 2021-11-18
PCT/US2021/010059 WO2022132195A2 (en) 2020-12-15 2021-12-15 Compositions and methods for modulation myc expression

Publications (1)

Publication Number Publication Date
AU2021401231A1 true AU2021401231A1 (en) 2023-06-29

Family

ID=82060102

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021401231A Pending AU2021401231A1 (en) 2020-12-15 2021-12-15 Compositions and methods for modulating myc expression

Country Status (8)

Country Link
US (1) US20240132559A1 (enExample)
EP (1) EP4262849A4 (enExample)
JP (1) JP2023553490A (enExample)
KR (1) KR20230120138A (enExample)
AU (1) AU2021401231A1 (enExample)
CA (1) CA3205133A1 (enExample)
MX (1) MX2023007116A (enExample)
WO (1) WO2022132195A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049075A1 (en) 2016-09-07 2018-03-15 Flagship Pioneering, Inc. Methods and compositions for modulating gene expression
CN115192714B (zh) * 2022-07-08 2024-09-17 沈阳药科大学 Hdac6抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途
TW202417012A (zh) * 2022-08-19 2024-05-01 美商旗艦先鋒創新公司 包含myc調節劑及檢查點抑制劑之組合療法
WO2024238723A1 (en) 2023-05-16 2024-11-21 Omega Therapeutics, Inc. Methods and compositions for modulating pcsk9 expression
JP2026518711A (ja) 2023-05-16 2026-06-09 フラッグシップ ラブズ １１４， インコーポレイテッド 標的遺伝子のメチル化を調節するための方法及び組成物
EP4716741A2 (en) * 2023-05-23 2026-04-01 Flagship Labs 114, Inc. Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
WO2025019742A1 (en) 2023-07-19 2025-01-23 Omega Therapeutics, Inc. Methods and compositions for modulating ctnnb1 expression
WO2025064469A1 (en) * 2023-09-18 2025-03-27 Omega Therapeutics, Inc. Methods for assessing dosage for epigenetic modifying agents
WO2025144907A1 (en) * 2023-12-27 2025-07-03 Flagship Pioneering Innovations V, Inc. Kinase inhibitors and particles comprising myc modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011972A1 (en) * 1995-09-28 1997-04-03 The Trustees Of Columbia University In The City Of New York Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof
GB201119904D0 (en) * 2011-11-17 2011-12-28 Univ Vilnius Analysis of methylation sites
WO2016103233A2 (en) * 2014-12-24 2016-06-30 Dana-Farber Cancer Institute, Inc. Systems and methods for genome modification and regulation
KR101900278B1 (ko) * 2016-04-18 2018-09-19 건국대학교 글로컬산학협력단 Myc-ap4 축 활성화된 암의 예방 또는 치료용 조성물의 스크리닝 방법
WO2018111944A1 (en) * 2016-12-12 2018-06-21 Whitehead Institute For Biomedical Research Regulation of transcription through ctcf loop anchors
WO2018183808A1 (en) * 2017-03-31 2018-10-04 Agenovir Corporation Antiviral therapeutic
US20190233805A1 (en) * 2017-10-04 2019-08-01 The Regents Of The University Of California Targetable proteins for epigenetic modification and methods for use thereof
EP3867368A4 (en) * 2018-10-15 2022-08-10 Flagship Pioneering Innovations V, Inc. DESTROYING THE ASSEMBLY OF A GENOMIC COMPLEX IN FUSION GENES
US11866469B2 (en) * 2019-02-06 2024-01-09 Klogenix Llc DNA binding proteins and uses thereof

Also Published As

Publication number Publication date
EP4262849A4 (en) 2024-10-30
MX2023007116A (es) 2024-01-08
KR20230120138A (ko) 2023-08-16
WO2022132195A3 (en) 2022-07-28
WO2022132195A2 (en) 2022-06-23
US20240132559A1 (en) 2024-04-25
CA3205133A1 (en) 2022-06-23
WO2022132195A8 (en) 2023-06-22
EP4262849A2 (en) 2023-10-25
JP2023553490A (ja) 2023-12-21

Similar Documents

Publication Publication Date Title
US20240132559A1 (en) Compositions and methods for modulating myc expression
US20230399640A1 (en) Compositions and methods for inhibiting gene expression
US20250375464A1 (en) Formulations for modulating myc expression
US20210322577A1 (en) Methods and systems for modifying dna
US20220403387A1 (en) Modulating genomic complexes
US20220348893A1 (en) Methods and compositions for modulating frataxin expression and treating friedrich's ataxia
US20230374549A1 (en) Compositions and methods for inhibiting the expression of multiple genes
WO2021061640A1 (en) Compositions and methods for modulating genomic complex integrity index
WO2024040229A2 (en) Combination therapies comprising myc modulators and checkpoint inhibitors
CN116829175A (zh) 用于调节myc表达的组合物和方法
TW202317601A (zh) 用於調節ｍｙｃ表現之組合物及方法
CA3196827A1 (en) Compositions and methods for inhibiting gene expression
EP4544055A2 (en) Combination therapies comprising myc modulation